PVLA
PALVELLA THERAPEUTICS, INC.
Key Financials
Operating Income
$-38602000
↓ 173.9%
Revenue
$42.8M
↑ 65.3%
Net Income
$-41715000
↓ 139.3%
EPS (Diluted)
$-3.71
↑ 52.6%
Total Liabilities
$31.6M
↑ 23.2%
Total Assets
$59.6M
↓ 32.5%
Shareholders' Equity
$28.0M
↓ 55.3%
Cash & Equivalents
$58.0M
↓ 30.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G | 8/10/2026 | View on SEC |
| S-8 | 8/4/2026 | View on SEC |
| 10-Q | 8/4/2026 | View on SEC |
| 8-K | 8/4/2026 | View on SEC |
| SCHEDULE 13G | 8/3/2026 | View on SEC |
| SCHEDULE 13G | 7/29/2026 | View on SEC |
| 4 | 7/17/2026 | View on SEC |
| 144 | 7/15/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | PVLA |
| Company Name | PALVELLA THERAPEUTICS, INC. |
| CIK | 1583648 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | NV |
| Phone | (484) 253-1461 |